Your browser doesn't support javascript.
loading
Recursive Partitioning Analysis for Local Control Achieved With Stereotactic Body Radiation Therapy for the Liver, Spine, or Lymph Nodes.
Kowalchuk, Roman O; Waters, Michael R; Dutta, Sunil W; Mack, Marie L; Richardson, K Martin; Spencer, Kelly; Romano, Kara D; Larner, James M; Sheehan, Jason P; Kersh, C Ronald.
Afiliación
  • Kowalchuk RO; University of Virginia, Riverside, Radiosurgery Center, Newport News, Virginia.
  • Waters MR; University of Virginia, Riverside, Radiosurgery Center, Newport News, Virginia.
  • Dutta SW; Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia.
  • Mack ML; School of Medicine, University of Virginia, Charlottesville, Virginia.
  • Richardson KM; University of Virginia, Riverside, Radiosurgery Center, Newport News, Virginia.
  • Spencer K; University of Virginia, Riverside, Radiosurgery Center, Newport News, Virginia.
  • Romano KD; Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia.
  • Larner JM; Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia.
  • Sheehan JP; Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.
  • Kersh CR; University of Virginia, Riverside, Radiosurgery Center, Newport News, Virginia.
Adv Radiat Oncol ; 6(3): 100612, 2021.
Article en En | MEDLINE | ID: mdl-34195484
ABSTRACT

PURPOSE:

This study aims to develop a local control risk stratification using recursive partitioning analysis (RPA) for patients receiving stereotactic body radiation therapy (SBRT) for metastatic cancer. METHODS AND MATERIALS A single institutional database of 397 SBRT treatments to the liver, spine, and lymph nodes was constructed. All treatments required imaging follow-up to assess for local control. Cox proportional hazards analysis was implemented before the decision tree analysis. The data were split into training (70%), validation (10%), and testing (20%) sets for RPA to optimize the training set.

RESULTS:

In the study, 361 treatments were included in the local control analysis. Two-year local control was 71%. A decision tree analysis was used and the resulting model demonstrated 93.10% fidelity for the validation set and 87.67% for the test set. RPA class 3 was composed of patients with non-small cell lung cancer (NSCLC) primary tumors and treatment targets other than the cervical, thoracic, and lumbar spines. RPA class 2 included patients with primary cancers other than NSCLC or breast and treatments targets of the sacral spine or liver. RPA class 1 consisted of all other patients (including lymph node targets and patients with primary breast cancer). Classes 3, 2, and 1 demonstrated 3-year local controls rates of 29%, 50%, and 83%, respectively. On subgroup analysis using the Kaplan-Meier method, treatments for lymph nodes and primary ovarian disease demonstrated improved local control relative to other treatment targets (P < .005) and primary disease sites (P < .005), respectively.

CONCLUSIONS:

A local control risk stratification model for SBRT to sites of metastatic disease was developed. Treatment target and primary tumor were identified as critical factors determining local control. NSCLC primary lesions have increased local failure for targets other than the cervical, thoracic, or lumbar spines, and improved local control was identified for lymph node sites and breast or ovarian primary tumors.

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Adv Radiat Oncol Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Adv Radiat Oncol Año: 2021 Tipo del documento: Article